Earnings Preview For Stevanato Gr

Stevanato Gr (NYSE:STVN) is set to give its latest quarterly earnings report on Thursday, 2023-05-04. Here’s what investors…

Stevanato Gr (NYSE:STVN) is set to give its latest quarterly earnings report on Thursday, 2023-05-04. Here’s what investors need to know before the announcement.

Analysts estimate that Stevanato Gr will report an earnings per share (EPS) of $0.13.

Stevanato Gr bulls will hope to hear the company announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Historical Earnings Performance

Last quarter the company beat EPS by $0.02, which was followed by a 7.13% increase in the share price the next day.

Here’s a look at Stevanato Gr’s past performance and the resulting price change:

Quarter Q4 2022 Q3 2022 Q2 2022 Q1 2022
EPS Estimate 0.17 0.13 0.12 0.11
EPS Actual 0.19 0.10 0.13 0.12
Price Change % 7.13% -0.97% 5.13% -0.21%

eps graph

Stock Performance

Shares of Stevanato Gr were trading at $27.48 as of May 02. Over the last 52-week period, shares are up 87.97%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.

To track all earnings releases for Stevanato Gr visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Organic Growth And Innovation Drive YoY Increase In Cannabis Producer Organigram’s Q4 Revenue And Adjusted EBITDA

Canadian cannabis producer Organigram Holdings reported an 11% year-over-year increase in net revenue for the fourth quarter, reaching C$A161.6 million ($121 million). The company credited the growth to its focus on innovative products that meet consumer demand for convenience, such as pre-rolls and edibles. The increase in revenue contributed to a 71% rise in adjusted EBITDA to nearly CA$6m for the quarter, compared with the same period in 2022. Organigram's adjusted gross margin was CA$40.2m, up 20% on 2022. The company also reported a net loss of CA$248.6m, compared with CA$14.3m in 2022, due to impairments on property, plant and equipment, intangibles and goodwill. Organigram said it expects improved margins in future as efficiency gains from facility upgrades and expansion into higher-margin categories such as craft flower and vapes bear fruit.

OGI